{"podcast":{"title":"Business News Today | 2 Min News | The Daily News Now!","slug":"business-finance-news-today-2-min-news-the-daily-news-now-7726192","podcast_index_feed_id":7726192,"rss_url":"https://feeds.fastcast.ai/the-daily-news-now-business.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/cover/a77b5c94-431e-4490-8653-1f676f1da586.png","author":"The Daily News Now!","episode_count":2000,"summary":"Hosted by Corey with the Story, Business News Today is your daily source for the latest headlines and stories shaping the world of business, finance, and the global economy. From market trends and corporate earnings to startups, entrepreneurship, technology, real estate, consumer trends, and economic policy, we bring you the business news that matters most—in just a few minutes. Whether you're an entrepreneur, investor, executive, business owner, or simply someone who wants to stay informed, Business News Today delivers clear, concise updates to help you understand the forces shaping the economy and the future of business. Business News Today — Business news, all in one place. Powered by AI.","last_synced_at":"2026-09-17T06:21:31.382927+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192"},"episode":{"title":"Pfizer’s Monthly Shot Could Shake Up Weight Loss Market","slug":"pfizer-s-monthly-shot-could-shake-up-weight-loss-market","published_at":"2026-06-12T17:23:41+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/pfizer-s-monthly-shot-could-shake-up-weight-loss-market","show_page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192","url":"https://api.fastcast.ai/audio/8eb6d558-41f4-45e0-81ea-407f8bc9b708.mp3","audio_url":"https://api.fastcast.ai/audio/8eb6d558-41f4-45e0-81ea-407f8bc9b708.mp3","summary":"Pfizer is poised to disrupt the booming weight-loss drug market with berobenatide, a once-monthly injection that could outshine weekly shots from Novo Nordisk and Eli Lilly—offering patients greater convenience and potentially better long-term adherence. With the market projected to hit $150 billion by 2035, Pfizer’s multi-trial approach for both weight loss and type 2 diabetes signals serious intent. While current competitors may still edge ahead in early results, Pfizer’s focus on accessibility could shift the game—and force investors to watch closely as the race for dominance heats up. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/d7c155417b83aef1","meta_description":"Pfizer is poised to disrupt the booming weight-loss drug market with berobenatide, a once-monthly injection that could outshine weekly shots from Novo Nor…","key_points":[],"chapters":[],"topics":[],"duration_seconds":115,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/pfizer-s-monthly-shot-could-shake-up-weight-loss-market/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/pfizer-s-monthly-shot-could-shake-up-weight-loss-market.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}